Page 24 - GTM-2-1

Global Translational Medicine Mineralocorticoid receptor in CMD

https://doi.org/10.1152/ajpregu.00316.2021 https://doi.org/10.1111/dom.13539
119. Ferguson D, Hutson I, Tycksen E, et al., 2020, Role of 129. Dirckx N, Morer MC, Clemens TL, et al., 2019, The role
mineralocorticoid receptor in adipogenesis and obesity in of osteoblasts in energy homeostasis. Nat Rev Endocrinol,
male mice. Endocrinology, 161: bqz010. 15: 651–665.
https://doi.org/10.1210/endocr/bqz010 https://doi.org/10.1038/s41574-019-0246-y
120. Lefranc C, Friederich-Persson M, Foufelle F, et al., 2021, 130. Lee NK, Sowa H, Hinoi E, et al., 2007, Endocrine regulation
Adipocyte-mineralocorticoid receptor alters mitochondrial of energy metabolism by the skeleton. Cell, 130: 456–469.
quality control leading to mitochondrial dysfunction and https://doi.org/10.1016/j.cell.2007.05.047
senescence of visceral adipose tissue. Int J Mol Sci, 22: 2881.
131. Yi Y, Du L, Qin M, et al., 2019, Regulation of atrial fibrosis by
https://doi.org/10.3390/ijms22062881 the bone. Hypertension, 73: 379–389.
121. Feraco A, Armani A, Urbanet R, et al., 2018, Minor role of
mature adipocyte mineralocorticoid receptor in high fat https://doi.org/10.1161/hypertensionaha.118.11544
induced obesity. J Endocrinol, 239: 229-240. 132. Wang YL, Bai L, Shi XR, et al., 2022, Osteoblast MR
deficiency protects against adverse ventricular remodeling
https://doi.org/10.1530/joe-18-0314
after myocardial infarction. J Mol Cell Cardiol, 167: 40–51.
122. Hayakawa T, Minemura T, Onodera T, et al., 2018, Impact
of MR on mature adipocytes in high-fat/high-sucrose diet- https://doi.org/10.1016/j.yjmcc.2022.03.003
induced obesity. J Endocrinol, 239: 63–71. 133. Rico-Mesa JS, White A, Ahmadian-Tehrani A, et al., 2020,
Mineralocorticoid receptor antagonists: A comprehensive
https://doi.org/10.1530/joe-18-0026
review of finerenone. Curr Cardiol Rep, 22: 140.
123. Kuhn E, Bourgeois C, Keo V, et al., 2014, Paradoxical
resistance to high-fat diet-induced obesity and altered https://doi.org/10.1007/s11886-020-01399-7
macrophage polarization in mineralocorticoid receptor- 134. Liu LC, Schutte E, Gansevoort RT, et al., 2015, Finerenone:
overexpressing mice. Am J Physiol Endocrinol Metab, Third-generation mineralocorticoid receptor antagonist for
306: E75–E90. the treatment of heart failure and diabetic kidney disease.
Expert Opin Investig Drugs, 24: 1123–1135.
https://doi.org/10.1152/ajpendo.00323.2013
https://doi.org/10.1517/13543784.2015.1059819
124. Viengchareun S, Penfornis P, Zennaro MC, et al., 2001,
Mineralocorticoid and glucocorticoid receptors inhibit ucp 135. Kolkhof P, Borden SA, 2012, Molecular pharmacology
expression and function in brown adipocytes. Am J Physiol of the mineralocorticoid receptor: Prospects for novel
Endocrinol Metab, 280: E640–E649. therapeutics. Mol Cell Endocrinol, 350: 310–317.
https://doi.org/10.1152/ajpendo.2001.280.4.E640 https://doi.org/10.1016/j.mce.2011.06.025
125. Kuhn E, Lamribet K, Viengchareun S, et al., 2019, Ucp1 136. Pitt B, Zannad F, Remme WJ, et al., 1999, The effect of
transrepression in brown fat in vivo and mineralocorticoid spironolactone on morbidity and mortality in patients with
receptor anti-thermogenic effects. Ann Endocrinol (Paris), severe heart failure. Randomized aldactone evaluation study
80: 1–9. investigators. N Engl J Med, 341: 709–717.
https://doi.org/10.1016/j.ando.2018.04.018 https://doi.org/10.1056/NEJM199909023411001
126. Marzolla V, Feraco A, Gorini S, et al., 2020, The novel non- 137. Agarwal R, Kolkhof P, Bakris G, et al., 2021, Steroidal and
steroidal mr antagonist finerenone improves metabolic non-steroidal mineralocorticoid receptor antagonists in
parameters in high-fat diet-fed mice and activates cardiorenal medicine. Eur Heart J, 42: 152–161.
brown adipose tissue via ampk-atgl pathway. FASEB J,
34: 12450–12465. https://doi.org/10.1093/eurheartj/ehaa736
138. McMurray JJ, O’Meara E, 2004, Treatment of heart failure
https://doi.org/10.1096/fj.202000164R
with spironolactone--trial and tribulations. N Engl J Med,
127. Marzolla V, Feraco A, Limana F, et al., 2022, Class- 351: 526–528.
specific responses of brown adipose tissue to steroidal
and nonsteroidal mineralocorticoid receptor antagonists. https://doi.org/10.1056/nejmp048144
J Endocrinol Invest, 45: 215–220. 139. Ko DT, Juurlink DN, Mamdani MM, et al., 2006,
Appropriateness of spironolactone prescribing in heart failure
https://doi.org/10.1007/s40618-021-01635-z
patients: A population-based study. J Card Fail, 12: 205–210.
128. Thuzar M, Law WP, Dimeski G, et al., 2019, Mineralocorticoid
antagonism enhances brown adipose tissue function in https://doi.org/10.1016/j.cardfail.2006.01.003
humans: A randomized placebo-controlled cross-over 140. Wei L, Struthers AD, Fahey T, et al., 2010, Spironolactone
study. Diabetes Obes Metab, 21: 509–516. use and renal toxicity: Population based longitudinal

Volume 2 Issue 1 (2023) 18 https://doi.org/10.36922/gtm.v2i1.229